Jens‐Uwe Blohmer
0000-0002-7969-250X
Publication & Citation Trends
Most Cited Works
Publications
754 total
Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials
Cited by 548
OpenAlex
A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study
Cited by 682
OpenAlex
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
Cited by 2,080
OpenAlex
Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto—GBG 69): a randomised, phase 3 trial
Cited by 409
OpenAlex
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis PDF
Cited by 4,623
OpenAlex
Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers PDF
Cited by 1,021
OpenAlex
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial
Cited by 1,020
OpenAlex
Research Topics
Breast Cancer Treatment Studies
(344)
Cancer Treatment and Pharmacology
(156)
Breast Lesions and Carcinomas
(120)
Advanced Breast Cancer Therapies
(114)
HER2/EGFR in Cancer Research
(108)
Frequent Co-Authors
Affiliations
Goethe University Frankfurt
University of Udine
Royal Marsden NHS Foundation Trust
Memorial Sloan Kettering Cancer Center
Karolinska University Hospital